Dr. Monk on Bevacizumab in Recurrent Cervical Cancer

Bradley J. Monk, MD
Published: Monday, Jul 14, 2014

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the utility of bevacizumab in recurrent cervical cancer.

Monk says bevacizumab has been used in many solid tumors. Recently, it is being evaluated for use in ovarian cancer and there are a number of phase III trials in this space.

Bevacizumab also has a survival advantage in cervical cancer, Monk says. There are a number of young women, between the ages of 45-50 that are diagnosed with recurrent cervical cancer. Treatment options for these patients are limited, with a standard treatment of a platinum doublet. In a recently published study, bevacizumab in combination with standard chemotherapy delivers a statistically significant survival advantage.

Monk says he is hopeful that bevacizumab in combination with standard chemotherapy will receive FDA approval for this subset of patients.
 
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the utility of bevacizumab in recurrent cervical cancer.

Monk says bevacizumab has been used in many solid tumors. Recently, it is being evaluated for use in ovarian cancer and there are a number of phase III trials in this space.

Bevacizumab also has a survival advantage in cervical cancer, Monk says. There are a number of young women, between the ages of 45-50 that are diagnosed with recurrent cervical cancer. Treatment options for these patients are limited, with a standard treatment of a platinum doublet. In a recently published study, bevacizumab in combination with standard chemotherapy delivers a statistically significant survival advantage.

Monk says he is hopeful that bevacizumab in combination with standard chemotherapy will receive FDA approval for this subset of patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x